Skip to content

BIOKEY: what changed

BE 0719.913.808NACE 72.101, Research and development on biotechnologyOther company

Position among the sector peers

What moved between 2025 and 2026

Net result for the year
-€16,912
2025 · -€26,728+€9,816
Equity
-€220,187
2025 · -€203,275-€16,912
Cash
€2,036
2025 · €616+€1,420
Balance sheet total
€2,606
2025 · €1,931+€676

Largest movements

2025 to 2026
Assets
  • Cash +€1,420

    up €1,420 (+231%), from €616 to €2,036

    mainly Other debts (+€17,588) and Receivables within one year (+€946)

  • Receivables within one year -€946

    down €946 (-71.9%), from €1,315 to €369

  • Deferred charges and accrued income +€201

    new in 2026: €201

Equity and liabilities
  • Other debts +€17,588

    up €17,588 (+13.6%), from €128,897 to €146,485

  • Profit (loss) carried forward -€16,912

    down €16,912 (-7.5%), from -€226,525 to -€243,437

Income statement
  • Gross operating margin +€9,908

    up €9,908 (+38.1%), from -€25,987 to -€16,079

Change in the result, 2025 to 2026

effect on the result

For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.

Result 2025 -€26,728
Gross operating margin +€9,908
Other operating charges -€20
Financial charges -€72
Result 2026 -€16,912
raises the resultlowers the result

Derived cash bridge

cash 2025 to 2026

The bridge is derived from the 2025 and 2026 balance sheets and the 2026 result. There is no filed cash-flow statement. You see where the money came from and where it went.

From operations +€1,420
Investment €0
Financing €0
Cash 2025 €616
Net result for the year -€16,912
Receivables within one year +€946
Deferred charges and accrued income -€201
Other debts +€17,588
Cash 2026 €2,036
brings cash intakes cash out
Every line side by side 27 lines
Line Code 2025 2026 Change %
Total assets 20/58 €1,931 €2,606 +€676 +35.0%
Current assets 29/58 €1,931 €2,606 +€676 +35.0%
Amounts receivable within one year 40/41 €1,315 €369 -€946 -71.9%
Other amounts receivable 41 €1,315 €369 -€946 -71.9%
Cash at bank and in hand 54/58 €616 €2,036 +€1,420 +231%
Deferred charges and accrued income 490/1 - €201 +€201
Total equity and liabilities 10/49 €1,931 €2,606 +€676 +35.0%
Equity 10/15 -€203,275 -€220,187 -€16,912 -8.3%
Contributions 10/11 €23,250 €23,250 = 0.0%
Profit (loss) carried forward 14 -€226,525 -€243,437 -€16,912 -7.5%
Amounts payable 17/49 €205,205 €222,793 +€17,588 +8.6%
Amounts payable after more than one year 17 €76,308 €76,308 = 0.0%
Other amounts payable 178/9 €76,308 €76,308 = 0.0%
Amounts payable within one year 42/48 €128,897 €146,485 +€17,588 +13.6%
Trade debts 44 €0 - =
Suppliers 440/4 €0 - =
Other amounts payable 47/48 €128,897 €146,485 +€17,588 +13.6%
Other operating charges 640/8 €698 €718 +€20 +2.9%
Gross operating margin 9900 -€25,987 -€16,079 +€9,908 +38.1%
Operating profit (loss) 9901 -€26,684 -€16,797 +€9,888 +37.1%
Financial income 75/76B €0 - =
Recurring financial income 75 €0 - =
Financial charges 65/66B €44 €115 +€72 +165%
Recurring financial charges 65 €44 €115 +€72 +165%
Profit (loss) for the period before taxes 9903 -€26,728 -€16,912 +€9,816 +36.7%
Profit (loss) for the period 9904 -€26,728 -€16,912 +€9,816 +36.7%
Profit (loss) for the period to be appropriated 9905 -€26,728 -€16,912 +€9,816 +36.7%

Value

latest balance sheet 30-04-2026 · indication, not a valuation or advice

Indicative value of the equity

Indication, not a valuation or advice

Capitalisation rate 12% result over 3 years earnings weight 50%

Worked out with Checked's starting values, not your estimate and not market data. Change the assumptions: the value follows.

The filed figures and these assumptions give no positive value. The adjusted equity and the average result are both zero or negative.

Part of the calculation comes out below zero. A shareholding is never worth less than zero, so the floor is zero.

Adjusted equity -€220,187

Adjusted equity

balance sheet 30-04-2026
Equity (10/15)
-€220,187
Revaluation of assets
€0
Deferred tax on the revaluation
€0
Other adjustment
€0
Adjusted equity
-€220,187

Capitalised earnings

net result for the year (9904)
2026
-€16,912
2025
-€26,728
2024
-€48,865
2023
-€54,899
2022
-€5,418
Average result
-€30,835
Divided by the capitalisation rate
14% / 12% / 10%
Capitalised earnings
not meaningful, as the average result is zero or negative

Limits of the indication

  • Checked holds no market prices or comparable transactions.
  • Anything after the latest accounts and items off the balance sheet (guarantees, leases, disputes) are left out.
  • Checked does not know the real value of buildings, stock and receivables. Enter your own revaluation or adjustment for it.
  • The result is not corrected for the manager's pay. If the company pays less or more than a market salary, the capitalised earnings are too high or too low.
  • The owner's role in the business, synergies for a buyer and the tax consequences of a sale are left out.

For a valuation to base a decision on, go to a company auditor or a certified accountant.

Calculation and sources

Source: filed annual accounts (NBB) and main activity (KBO). The movements compare the financial years ended 30 April 2025 and 30 April 2026. Green is a favourable move for that line, red an unfavourable one. The value is an indication, not a valuation or advice. Prepared on 15 November 2026 via checked.be.